Ziprasidone HCL (oral)
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia and Disorders With Psychotic Features
Conditions
Schizophrenia and Disorders With Psychotic Features
Trial Timeline
Dec 1, 2008 → May 1, 2012
NCT ID
NCT00748566About Ziprasidone HCL (oral)
Ziprasidone HCL (oral) is a approved stage product being developed by Pfizer for Schizophrenia and Disorders With Psychotic Features. The current trial status is terminated. This product is registered under clinical trial identifier NCT00748566. Target conditions include Schizophrenia and Disorders With Psychotic Features.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia and Disorders With Psychotic Features were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01113541 | Phase 3 | Terminated |
| NCT00748566 | Approved | Terminated |
Competing Products
20 competing products in Schizophrenia and Disorders With Psychotic Features